All news articles – Page 5
-
NewsLilly chooses Pennsylvania for $3.5bn injectables manufacturing facility
Investment in the Lehigh Valley site finalises the last of the pharma company’s four new US manufacturing plants, supporting its onshoring of domestic medicine production.
-
NewsSever Pharma Solutions appoints Niklas Lindgren as VP of Quality
He joins the Swedish CDMO from medical device company Dignitana.
-
NewsAstraZeneca makes $15bn manufacturing investment in China
Landmark, decade-long investment plan aims to support the pharma company’s 2030 revenue objective of $80 billion.
-
NewsModerna and Recordati collaborate on rare disease mRNA therapy
License agreement set to advance mRNA-3927, a potential disease modifying therapy for the rare metabolic disorder propionic acidemia.
-
NewsRoche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
-
NewsPharma benefits in EU-India Free Trade Agreement
Conclusion of ‘landmark’ deal significantly enhances trade, investment and supply chains, notably granting beneficial tariff reductions for the pharma industry.
-
NewsDr Michael J. Miller joins Spore.Bio as VP of Scientific and Regulatory Affairs
The French start-up focuses on advancing rapid microbiology in manufacturing quality control.
-
NewsFMT shows promise for enhancing immunotherapy effectiveness in advanced cancer
Phase II data derived from the first randomised trial comparing immunotherapy outcomes post-FMT from immunotherapy responders versus placebo.
-
NewsInnovative nanoparticle research could restore antibiotic efficacy
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
-
NewsIpsen selects Pierrick Lefranc as new EVP Technical Operations
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.
-
NewsUK ‘gaining pace’ with early-stage trials for advanced therapies
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
-
NewsWuXi Biologics partners with HanchorBio on next-gen immunotherapies
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
-
NewsAdvanced manufacturing research supports automated production of critical API
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
-
NewsHoth Therapeutics’ topical therapy shines in cancer toxicity trial
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
-
NewsModerna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
New phase IIb data highlights the combination’s potential to offer improved efficiency to high-risk melanoma patients.
-
NewsGenentech doubles investment in North Carolina manufacturing facility
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
-
NewsEurope marks key milestone in adopting Critical Medicines Act
EU Parliament agrees clear priorities for future negotiations on the act, including investing in pharma manufacturing capacity.
-
NewsGSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
-
News
Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
-
NewsEU concludes major free trade agreement with Mercosur countries
European pharma industry acknowledges the progress made, particularly with partial tariff reductions, but said further provisions could have been achieved.